Advanced Filters
noise
Found 64,778 clinical trials
M Maël HEIBLIG, MD

Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis

In transfusion-dependent myelodysplastic syndromes patients, regular blood transfusions lead to iron overload, which can cause organ damage, hormonal imbalances, and increased infection risk, ultimately impacting patient survival. Standard oral iron chelation therapies can be intolerable for some patients due to adverse effects. The MEX-CD1 device (class III) could potentially offer …

18 years of age All Phase N/A

Clinical Performance of Metal Ceramic Fixed Dental Prostheses Using Two Porcelain Veneering Systems: A Randomized Clinical Trial

This study aims to evaluate the clinical performance of metal ceramic fixed dental prostheses veneered with two porcelain systems; Vintage Pro and IPS style ceram and cemented with Beautilink SA cement.

21 - 80 years of age All Phase N/A
P Pam L Sloan, RN

Magnesium and Cramping

Hysteroscopy (an exam to look inside the uterus) is one of the most frequently performed procedures for patients with cervical or uterine disorders. It is the gold standard for evaluating various intrauterine problems, pre-menopausal and post-menopausal abnormal uterine bleeding, as well as being a vital examination modality for infertility work-up. …

18 years of age Female Phase 4
S Santiago Sanchez Cabús

The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy

The purpose of this trial is to evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy.

18 years of age All Phase N/A
J Jeanne RIVERAIN, MD

Long-term Cognitive and Functional Impact of Proton-therapy or Modern Fractionated Radiotherapy in Cavernous Sinus Meningioma: An Open-label Randomized 1:1 Phase III Study

Cavernous sinus meningiomas are close to optic nerve, pituitary gland, cranial nerve, and hippocampi. The doses delivered to these structures are crucial and radiotherapy of cavernous sinus meningiomas exposes patients to late secondary effects (pituitary deficit, nerve palsy, cognitive impairment…). In 2012, Gondi reported that a dose given to 40% …

18 - 70 years of age All Phase N/A
M Meg Thomas

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

The purpose of this study, known as DISCERN, is to compare two different treatments for a type of lung cancer called non-small cell lung cancer (NSCLC) that does not show a marker known as PD-L1. This study will help us understand if using two types of immune therapy together with …

18 - 89 years of age All Phase 2
A Ahmad Mahan

The Effects of Core Shamanism in Fibromyalgia

This study aims to determine the feasibility of a shamanism intervention for patients with fibromyalgia, acquire efficacy data to determine if Shamanism reduces clinical pain and other common symptoms associated with fibromyalgia, and determine if the Shamanism intervention changes heart rate electrocardiogram (ECG), breathing rate, and brain wave electroencephalogram (EEG) …

18 - 75 years of age Female Phase N/A
A Abdullah Al Maruf, PhD, M.Pharm, B.Pharm

Pharmacogenomics-Supported Psychotropic Prescribing Trial

Investigate the feasibility and utility of implementing pharmacogenetic testing for adults (aged 18 and older) seeking care for mental illness in Manitoba.

18 years of age All Phase N/A
S Stanislav Sirakov, Prof.

LUMENS-1 EU EFS CIP

The primary objective of this clinical investigation is to evaluate the early safety and feasibility of the LuSeed Aneurysm Embolization System for treating unruptured intracranial aneurysms (IA). This is a prospective, single-arm, open-label, multi-center, interventional study, screening patients approved for treatment of unruptured IAs based on national or international guidelines. …

18 - 80 years of age All Phase N/A
J Jeffrey Cheng, MD, PhD

Correction of Psoriatic T Cell Signatures by Deucravacitinib

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

18 - 75 years of age All Phase 4

Simplify language using AI